Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue 1.4 Market Analysis by Type 1.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Sildenafil 1.4.3 Tadalafil 1.4.4 Avanafil 1.4.5 Vardenafil 1.5 Market by Application 1.5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2020 VS 2026 1.5.2 Hospital 1.5.3 Retail Pharmacy 1.5.4 Online Pharmacies 1.5.5 Other 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Perspective (2015-2026) 2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Growth Trends by Regions 2.2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Share by Regions (2015-2020) 2.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Strategy 2.3.6 Primary Interviews with Key Phosphodiesterase Type 5 (PDE5) Inhibitor Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Market Size 3.1.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue (2015-2020) 3.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Players (2015-2020) 3.1.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio 3.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2019 3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players Head office and Area Served 3.4 Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service 3.5 Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Type (2015-2020) 4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2021-2026) 5 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Application (2015-2026) 5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020) 6.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in North America (2019-2020) 6.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) 6.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 7 Europe 7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020) 7.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Europe (2019-2020) 7.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) 7.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 8 China 8.1 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020) 8.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in China (2019-2020) 8.3 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) 8.4 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 9 Japan 9.1 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020) 9.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Japan (2019-2020) 9.3 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) 9.4 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020) 10.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) 10.4 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 11 India 11.1 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020) 11.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in India (2019-2020) 11.3 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) 11.4 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020) 12.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Central & South America (2019-2020) 12.3 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) 12.4 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Eli Lilly 13.1.1 Eli Lilly Company Details 13.1.2 Eli Lilly Business Overview and Its Total Revenue 13.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.1.4 Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)) 13.1.5 Eli Lilly Recent Development 13.2 Pfizer 13.2.1 Pfizer Company Details 13.2.2 Pfizer Business Overview and Its Total Revenue 13.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.2.4 Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.2.5 Pfizer Recent Development 13.3 Bayer 13.3.1 Bayer Company Details 13.3.2 Bayer Business Overview and Its Total Revenue 13.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.3.4 Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.3.5 Bayer Recent Development 13.4 Novartis AG 13.4.1 Novartis AG Company Details 13.4.2 Novartis AG Business Overview and Its Total Revenue 13.4.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.4.4 Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.4.5 Novartis AG Recent Development 13.5 Merck 13.5.1 Merck Company Details 13.5.2 Merck Business Overview and Its Total Revenue 13.5.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.5.4 Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.5.5 Merck Recent Development 13.6 GlaxoSmithKline plc 13.6.1 GlaxoSmithKline plc Company Details 13.6.2 GlaxoSmithKline plc Business Overview and Its Total Revenue 13.6.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.6.4 GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.6.5 GlaxoSmithKline plc Recent Development 13.7 Roche 13.7.1 Roche Company Details 13.7.2 Roche Business Overview and Its Total Revenue 13.7.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.7.4 Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.7.5 Roche Recent Development 13.8 AstraZeneca 13.8.1 AstraZeneca Company Details 13.8.2 AstraZeneca Business Overview and Its Total Revenue 13.8.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.8.4 AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.8.5 AstraZeneca Recent Development 13.9 BaiYunShan General Factory 13.9.1 BaiYunShan General Factory Company Details 13.9.2 BaiYunShan General Factory Business Overview and Its Total Revenue 13.9.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.9.4 BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.9.5 BaiYunShan General Factory Recent Development 13.10 SK Chemicals 13.10.1 SK Chemicals Company Details 13.10.2 SK Chemicals Business Overview and Its Total Revenue 13.10.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 13.10.4 SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 13.10.5 SK Chemicals Recent Development 13.11 Teva Pharma 10.11.1 Teva Pharma Company Details 10.11.2 Teva Pharma Business Overview and Its Total Revenue 10.11.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 10.11.4 Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 10.11.5 Teva Pharma Recent Development 13.12 Dong-A ST 10.12.1 Dong-A ST Company Details 10.12.2 Dong-A ST Business Overview and Its Total Revenue 10.12.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 10.12.4 Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 10.12.5 Dong-A ST Recent Development 13.13 Metuchen Pharma 10.13.1 Metuchen Pharma Company Details 10.13.2 Metuchen Pharma Business Overview and Its Total Revenue 10.13.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 10.13.4 Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 10.13.5 Metuchen Pharma Recent Development 13.14 Seoul Pharma 10.14.1 Seoul Pharma Company Details 10.14.2 Seoul Pharma Business Overview and Its Total Revenue 10.14.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 10.14.4 Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 10.14.5 Seoul Pharma Recent Development 13.15 Vectura Group 10.15.1 Vectura Group Company Details 10.15.2 Vectura Group Business Overview and Its Total Revenue 10.15.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction 10.15.4 Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) 10.15.5 Vectura Group Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Phosphodiesterase Type 5 (PDE5) Inhibitor Key Market Segments Table 2. Key Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Table 3. Ranking of Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Sildenafil Table 6. Key Players of Tadalafil Table 7. Key Players of Avanafil Table 8. Key Players of Vardenafil Table 9. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 10. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (US$ Million): 2020 VS 2026 Table 11. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (2015-2020) (US$ Million) Table 12. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2015-2020) Table 13. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 14. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2021-2026) Table 15. Market Top Trends Table 16. Key Drivers: Impact Analysis Table 17. Key Challenges Table 18. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Strategy Table 19. Main Points Interviewed from Key Phosphodiesterase Type 5 (PDE5) Inhibitor Players Table 20. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Players (2015-2020) (Million US$) Table 21. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players (2015-2020) Table 22. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2019) Table 23. Global Phosphodiesterase Type 5 (PDE5) Inhibitor by Players Market Concentration Ratio (CR5 and HHI) Table 24. Key Players Headquarters and Area Served Table 25. Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service Table 26. Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 29. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Type (2015-2020) Table 30. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2021-2026) Table 31. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Application (2015-2020) Table 32. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 33. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Application (2021-2026) Table 34. North America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$) Table 35. North America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020) Table 36. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 37. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020) Table 38. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 39. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020) Table 40. Europe Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$) Table 41. Europe Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020) Table 42. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 43. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020) Table 44. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 45. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020) Table 46. China Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$) Table 47. China Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020) Table 48. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 49. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020) Table 50. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 51. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020) Table 52. Japan Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$) Table 53. Japan Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020) Table 54. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 55. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020) Table 56. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 57. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020) Table 58. Southeast Asia Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$) Table 59. Southeast Asia Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020) Table 60. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 61. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020) Table 62. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 63. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020) Table 64. India Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$) Table 65. India Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020) Table 66. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 67. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020) Table 68. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 69. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020) Table 70. Central & South America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$) Table 71. Central & South America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020) Table 72. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$) Table 73. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020) Table 74. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$) Table 75. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020) Table 76. Eli Lilly Company Details Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Product Table 79. Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 80. Eli Lilly Recent Development Table 81. Pfizer Company Details Table 82. Pfizer Business Overview Table 83. Pfizer Product Table 84. Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 85. Pfizer Recent Development Table 86. Bayer Company Details Table 87. Bayer Business Overview Table 88. Bayer Product Table 89. Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 90. Bayer Recent Development Table 91. Novartis AG Company Details Table 92. Novartis AG Business Overview Table 93. Novartis AG Product Table 94. Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 95. Novartis AG Recent Development Table 96. Merck Company Details Table 97. Merck Business Overview Table 98. Merck Product Table 99. Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 100. Merck Recent Development Table 101. GlaxoSmithKline plc Company Details Table 102. GlaxoSmithKline plc Business Overview Table 103. GlaxoSmithKline plc Product Table 104. GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 105. GlaxoSmithKline plc Recent Development Table 106. Roche Company Details Table 107. Roche Business Overview Table 108. Roche Product Table 109. Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 110. Roche Recent Development Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Product Table 113. AstraZeneca Company Details Table 114. AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 115. AstraZeneca Recent Development Table 116. BaiYunShan General Factory Company Details Table 117. BaiYunShan General Factory Business Overview Table 118. BaiYunShan General Factory Product Table 119. BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 120. BaiYunShan General Factory Recent Development Table 121. SK Chemicals Company Details Table 122. SK Chemicals Business Overview Table 123. SK Chemicals Product Table 124. SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 125. SK Chemicals Recent Development Table 126. Teva Pharma Company Details Table 127. Teva Pharma Business Overview Table 128. Teva Pharma Product Table 129. Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 130. Teva Pharma Recent Development Table 131. Dong-A ST Company Details Table 132. Dong-A ST Business Overview Table 133. Dong-A ST Product Table 134. Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 135. Dong-A ST Recent Development Table 136. Metuchen Pharma Company Details Table 137. Metuchen Pharma Business Overview Table 138. Metuchen Pharma Product Table 139. Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 140. Metuchen Pharma Recent Development Table 141. Seoul Pharma Company Details Table 142. Seoul Pharma Business Overview Table 143. Seoul Pharma Product Table 144. Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 145. Seoul Pharma Recent Development Table 146. Vectura Group Company Details Table 147. Vectura Group Business Overview Table 148. Vectura Group Product Table 149. Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$) Table 150. Vectura Group Recent Development Table 151. Research Programs/Design for This Report Table 152. Key Data Information from Secondary Sources Table 153. Key Data Information from Primary Sources List of Figures Figure 1. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type: 2020 VS 2026 Figure 2. Sildenafil Features Figure 3. Tadalafil Features Figure 4. Avanafil Features Figure 5. Vardenafil Features Figure 6. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2020 VS 2026 Figure 7. Hospital Case Studies Figure 8. Retail Pharmacy Case Studies Figure 9. Online Pharmacies Case Studies Figure 10. Other Case Studies Figure 11. Phosphodiesterase Type 5 (PDE5) Inhibitor Report Years Considered Figure 12. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth 2015-2026 (US$ Million) Figure 13. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions: 2020 VS 2026 Figure 14. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2021-2026) Figure 15. Porter's Five Forces Analysis Figure 16. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players in 2019 Figure 17. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2019 Figure 18. The Top 10 and 5 Players Market Share by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2019 Figure 19. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$) Figure 21. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$) Figure 24. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$) Figure 25. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$) Figure 26. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018 Figure 27. Eli Lilly Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 28. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 29. Pfizer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 30. Bayer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 31. Bayer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 32. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 33. Novartis AG Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 34. Merck Total Revenue (US$ Million): 2019 Compared with 2018 Figure 35. Merck Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 36. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 37. GlaxoSmithKline plc Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 38. Roche Total Revenue (US$ Million): 2019 Compared with 2018 Figure 39. Roche Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 40. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018 Figure 41. AstraZeneca Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 42. BaiYunShan General Factory Total Revenue (US$ Million): 2019 Compared with 2018 Figure 43. BaiYunShan General Factory Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 44. SK Chemicals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 45. SK Chemicals Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 46. Teva Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 47. Teva Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 48. Dong-A ST Total Revenue (US$ Million): 2019 Compared with 2018 Figure 49. Dong-A ST Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 50. Metuchen Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 51. Metuchen Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 52. Seoul Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 53. Seoul Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 54. Vectura Group Total Revenue (US$ Million): 2019 Compared with 2018 Figure 55. Vectura Group Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) Figure 56. Bottom-up and Top-down Approaches for This Report Figure 57. Data Triangulation Figure 58. Key Executives Interviewed

Eli Lilly Pfizer Bayer Novartis AG Merck GlaxoSmithKline plc Roche AstraZeneca BaiYunShan General Factory SK Chemicals Teva Pharma Dong-A ST Metuchen Pharma Seoul Pharma Vectura Group